Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)

Abstract : We report our experience on bendamustine and rituximab (BR) combination in 26 patients with chronic lymphocytic leukemia (CLL) complicated by autoimmune hemolytic anemia (AIHA). At the time of BR initiation, 88% of the patients had already been treated for AIHA and CLL was progressive regardless of AIHA in all patients but one. Overall response rates were 81% for AIHA and 77% for CLL. Median time to next treatment was 28.3 months and 26.2 months for AIHA and CLL, respectively. BR therapy may represent a good and safe therapeutic option in this setting where adequate control of CLL seems important for long-term AIHA response. Am. J. Hematol. 90:204–207, 2015.
Type de document :
Article dans une revue
American Journal of Hematology, Wiley, 2015, 90 (3), pp.204 - 207. 〈10.1002/ajh.23909〉
Liste complète des métadonnées

https://hal.univ-lorraine.fr/hal-01667670
Contributeur : Ngere Ul <>
Soumis le : mardi 19 décembre 2017 - 15:08:05
Dernière modification le : mercredi 16 mai 2018 - 11:23:18

Lien texte intégral

Identifiants

Citation

Anne Quinquenel, Christophe Willekens, Jehan Dupuis, Bruno Royer, Loïc Ysebaert, et al.. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). American Journal of Hematology, Wiley, 2015, 90 (3), pp.204 - 207. 〈10.1002/ajh.23909〉. 〈hal-01667670〉

Partager

Métriques

Consultations de la notice

28